Podcasts about american society

Dr. Chad Miller from Colorado State University shares his innovative approach to teaching horticulture through a classroom trade show format that transforms traditional plant identification courses into engaging, multidimensional learning experiences. As the 2024 ASHS Outstanding Undergraduate Educator award winner, he discusses how he combines plant knowledge with professional skill development to prepare students for success beyond the classroom.• Creating a trade show environment where students showcase plant knowledge creatively• Moving beyond memorization to develop professional communication skills• Using peer evaluation to help students learn to give and receive constructive feedback• Approaching teaching as scholarship worthy of research and publication• Balancing high expectations with understanding of students' complex lives• Finding joy in seeing students succeed professionally• Establishing a classroom culture where it's safe to not know and to learn from mistakesTo read more about Dr. Miller's teaching approach, check out his award-winning paper "Classroom Trade Show: An Alternative to Traditional Classroom Presentations in an Undergraduate Plant Identification Course" in HortTechnology. If you're interested in teaching innovations in horticulture, consider joining the ASHS Teaching Methods Interest Group.Learn more about the American Society for Horticultural Science (ASHS) at https://ashs.org/.HortTechnology, HortScience and the Journal of the American Society for Horticultural Science are all open-access and peer-reviewed journals, published by the American Society of Horticultural Science (ASHS). Find them at journals.ashs.org.Consider becoming an ASHS member at https://ashs.org/page/Becomeamember!You can also find the official webpage for Plants, People, Science at ashs.org/plantspeoplesciencepodcast, and we encourage you to send us feedback or suggestions at https://ashs.org/webinarpodcastsuggestion. Podcast transcripts are available at https://plantspeoplescience.buzzsprout.com.On LinkedIn find Sam Humphrey at linkedin.com/in/samson-humphrey. Curt Rom is at https://www.linkedin.com/in/curt-rom-611085134/. Lena Wilson is at https://www.linkedin.com/in/lena-wilson-2531a5141/. Thank you for listening! ...

In this episode of the DermSurgery Digest, you'll hear a summary of the cosmetic and general dermatology articles in the September 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Girish Munavalli, MD, and Isabela Jones, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the surgical oncology and reconstruction articles in the September issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the September 2025 issue of Dermatologic Surgery followed by commentary from special guest contributors Mark Russell, MD, and Ami Greene, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the September issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

In this episode of SurgOnc Today, we will discuss a few of the practice changing trials presented at the American Society of Clinical Oncology annual meeting this past June. The episode is moderated by Dr. Kelly Hewitt and offers insightful discussion by leaders in medical oncology, including Dr. Jo Chien, Dr. Laura Kennedy and Dr. William Gradishar.  Highlights include discussion of results from COMPASS Her2, SERENA-6 and the current state and utility of circulating tumor DNA in patients with early-stage breast cancer.

So I had the chance to sit down with Elesha Coffman, who's written what might be the only book entirely devoted to the Christian Century magazine, and we ended up diving deep into the whole messy question of what "mainline Protestantism" even means - which apparently stumped two past presidents of the American Society of Church History during her dissertation defense, with the best answer being something about railroads in Philadelphia. We talked through her journey from Christianity Today to studying the Christian Century, how these magazines both spoke to and sometimes wildly misjudged their audiences (especially around Billy Graham), and the cultural capital that tied together mainline Protestant clergy even when their theology and politics diverged from their congregations. What struck me was how the isolation of educated clergy - whether it's the 1920s pastor in North Dakota parceling out his weekly dose of seminary culture through the Christian Century, or today's mainline clergy feeling lonely in their own congregations - keeps showing up as this recurring theme in American church history. Plus, she's working on a book about the Religion News Service, which was apparently run by Jewish editors providing church news to Christian newspapers. This goes to show how much more complicated and interesting these stories get when you actually dig into the archives. Elesha Coffman is a historian of American Christianity and professor of history at Baylor University. She is the author of The Christian Century and the Rise of the Protestant Mainline and Turning Points in American Church History, as well as a biography of anthropologist Margaret Mead. UPCOMING ONLINE CLASS - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The God of Justice: Where Ancient Wisdom Meets Contemporary Longing⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ This transformative online class brings together distinguished scholars from biblical studies, theology, history, and faith leadership to offer exactly what our moment demands: the rich, textured wisdom of multiple academic disciplines speaking into our contemporary quest for justice. Here you'll discover how ancient texts illuminate modern struggles, how theological reflection deepens social action, and how historical understanding opens new possibilities for faithful engagement with our world's brokenness and beauty. Join John Dominic Crossan, Peter Enns, Casey Sigmon, Aizaiah Yong, & Malcolm Foley As always, the class is donation-based, including 0. INFO & Sign-Up at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.FaithAndPolitics.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Theology Beer Camp ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠is a unique three-day conference that brings together of theology nerds and craft beer for a blend of intellectual engagement, community building, and fun. Guests this year include John Dominic Crossan, Kelly Brown Douglas, Philip Clayton, Stacey Floyd-Thomas, Jeffery Pugh, Juan Floyd-Thomas, Andy Root, Grace Ji-Sun Kim, Noreen Herzfeld, Reggie Williams, Casper ter Kuile, and more! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get info and tickets here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. _____________________ This podcast is a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Homebrewed Christianity⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ production. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠the Homebrewed Christianity⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Theology Nerd Throwdown⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, & ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Rise of Bonhoeffer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ podcasts for more theological goodness for your earbuds. Join over 75,000 other people by joining our⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Substack - Process This!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get instant access to over 50 classes at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.TheologyClass.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow the podcast, drop a review⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, send ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠feedback/questions⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or become a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠member of the HBC Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textA hundred years ago, shantyboat communities could be found along many rivers in the US. Historian Gregg Andrews went in-depth to research these communities, inspired in part by the discovery of a personal connection to them, which resulted in a book called “Shantyboats and Roustabouts: The River Poor of St. Louis, 1875 to 1930.” In this episode, I talk with Gregg about those shantyboat communities. After Gregg describes how he got interested in shantyboat communities, he describes what a shantyboat was and who lived in them, what it was like to live in one of these communities and their frontier-like culture, some of the characters he came across, including Louis Seibt and Rose Mosenthein, the legal basis shantyboaters used to defend their communities (often successfully), and their eventual dissolution. 

Are you an EA or administrative professional who works with a Board of Directors? Want to sharpen your skills? Learn from expert Carissa Burgett. Recorded at EA Ignite Spring 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Check out my top picks for skin care here. Download the Free eBook 'Skincare Myths Busted' What do you do when the face in the mirror doesn't match how you feel inside? Welcome to the skin shift that happens in midlife — a direct result of hormonal changes, specifically the drop in estrogen that comes with perimenopause and menopause. And while it's common, it's not talked about enough. Until now. In this episode, I sit down with Dr. Pooja Rambhia, a board-certified dermatologist who's leading the conversation around what's been coined the “menopause makeover.” This is about understanding what's happening in your skin and body during menopause, and how to support both with science, compassion, and the right strategies. From collagen loss to skin laxity to the real reason your products aren't working anymore, we cover it all. We also talk about realistic solutions, from injectables and resurfacing lasers to hormone therapy and everyday skincare that actually supports your skin at this stage of life. This episode is not about “fixing” your face. It's about finally getting answers to the questions so many women are asking and doing so with a sense of clarity. Key Takeaways: Skin loses up to 30% of its collagen in the first five years after menopause. Estrogen is important for your skin's hydration, elasticity, thickness, and glow. It's normal to experience acne, dryness, sagging, and texture changes but that doesn't mean you have to just accept it. Bio-stimulatory injectables, topical actives, laser treatments, and even hormone replacement therapy can all play a role when used wisely and intentionally. Aging is not a decline. It's a transition that deserves support, not shame. Pooja H. Rambhia, MD, is a board-certified dermatologist with specialized fellowship training in cosmetic dermatology and laser surgery. She practices at UnionDerm in New York City and Greenwich, CT, providing comprehensive dermatologic care and specializing in laser treatments, injectables, and facial and body contouring for all skin types. Dr. Rambhia completed her medical training at Case Western Reserve University and dermatology residency at Zucker School of Medicine/Northwell Health, where she served as Chief Resident. She then completed the prestigious American Society for Dermatologic Surgery Fellowship at UnionDerm with Dr. Anne Chapas. Committed to advancing the field of dermatology, Dr. Rambhia has published numerous peer-reviewed articles in leading journals and presented her research at major national conferences including the American Academy of Dermatology and the American Society for Dermatologic Surgery. Her expertise has been featured in major media outlets including Vogue, Allure, Marie Claire, InStyle, Elle and The New York Times. Dr. Rambhia is dedicated to delivering personalized, natural-looking results while combining artistry with the latest scientific innovations in aesthetic dermatology. Follow Dr. Rambhia here: https://www.instagram.com/drpoojarambhia/?hl=en https://www.instagram.com/unionderm/?hl=en https://www.unionderm.com/ Download my Free Guide 'In My Perimenopause Era'

David Garland is Professor of Sociology in NYU's Department of Sociology and Arthur T. Vanderbilt Professor of Law at NYU School of Law. His area of research is social theory and historical sociology with a focus on the penal state and the welfare state. In 2012, the American Society of Criminology awarded him the Edwin H. Sutherland Prize for outstanding contributions to theory and research. He has been elected to membership of learned societies in both the United States and the United Kingdom, being a Fellow of the British Academy, the American Academy of Arts and Sciences, and the Royal Society of Edinburgh. 

America is facing deep political division. Republican vs. Democrat, Left vs. Right. But what will it truly take for us to come together as one nation again? On this episode, former California State Assemblyman Mike Gatto sits down with host and special guest co-host Joey for an honest conversation about America's current political climate. From the challenges facing both major parties to the growing frustration among citizens, Mike shares his perspective on what's fueling the divide and outlines practical steps everyday Americans can take to ensure their voices are heard by elected officials. Follow Mike Gatto: Website – www.mikegatto.com Twitter – @MikeGatto Follow Joey: TikTok – @joey_doesit

Send us a textDr. Michael Aziz, M.D. discusses his book: The Ageless Revolution: 10 Hallmarks of Aging That Hold the Secret to Defeating Disease, reversing age, Looking Younger, and Living Longer. Dr. Michael Aziz is a board-certified Internal Medicine physician, author, and a broadcast media commentator. He is as an attending physician at Lenox Hill Hospital in New York City. Dr. Aziz completed his medical training at Long Island Jewish Medical Center and Staten Island University Hospital in New York. He is a member of the American College of Physicians,  the American Society of Internal Medicine, and a fellow of the Royal Society of Medicine in the United Kingdom. Dr. Aziz has also been a keynote speaker at numerous national and international conferences, including those organized by the American Academy of Anti-Aging Medicine.You can find him at: www.michaelazizmd.com

Episode 061 | Arisa E. Ortiz, MD is the Founder/Creator of Your Pre-Visit, Director of Laser and Cosmetic Dermatology, and a Clinical Professor of Dermatology at the University of California, San Diego. She received training in Mohs Micrographic Surgery at UC San Diego and also completed the prestigious cosmetic and laser fellowship at Massachusetts General Hospital, Harvard Medical School, and Wellman Center for Photomedicine. Dr. Ortiz completed her dermatology residency training at UC Irvine and Beckman Laser Institute. She has authored over sixty publications and several book chapters. Dr. Ortiz also coedited a textbook on surgical reconstruction. She has presented at international and national conferences and is frequently an invited speaker at the American Academy of Dermatology (AAD), American Society for Dermatologic Surgery (ASDS), and the American Society for Laser Medicine and Surgery (ASLMS). She is on the editorial board of the Journal of Lasers in Surgery and Medicine and has won several awards including the ASLMS Dr. Horace Furumoto Young Investigator Award and ASLMS Best of Session Award for Cutaneous Applications, ASDS President's Outstanding Service Award, Castle Connolly Top Doctors Award, Exceptional Women in Medicine, and Newsweek America's Best Dermatologists. She has also been featured on The Doctors & Dr. Pimple Popper. Dr. Ortiz has served as the President of the San Diego Dermatologic Surgery Society and President of ASLMS. Her research interests are in laser treatment of non-melanoma skin cancer.This episode was recorded on March 24th, 2025.Connect with and learn from Dr. Rubin and SEENArisa Ortiz, MD (arisaortiz@gmail.com)Dr. Ortiz on IGYour Pre-Visit (Use code DERM60 for an extended free trial!)YPV on IGMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.Above & Beyond DermatologyNutrafol -- special pricing and physician exclusive productsNeoGenesis -- my favorite source of stem cell released molecules for skin/hairSilagen.biz -- physician dispensed scar refinement products delivered to your door (use practice code 1206240832P)NewsletterLinkedInFacebookDr. Lewellis on InstagramAbove & Beyond Dermatology on InstagramYouTubeTikTokTwitter/XChange Your Mind, Change Your LifeSoMeDocs (Doctors on Social Media)Pippa!

We're told vitamins are essential for our health. That they boost our immune systems, fight fatigue, and protect us from disease. But what if most of it isn't true? In the 20th century, vitamin supplements were hailed as a breakthrough, curing diseases like scurvy and rickets. But that success story took a turn. In the US, a law passed in 1994 — helped by a Hollywood ad campaign — removed almost all oversight from the supplement industry. Since then, a $40 billion business has grown in the shadows. One where marketing beats science, and health claims are made with barely any evidence. Dr. David Seres is Director of Medical Nutrition and a Professor at Columbia University's Institute of Human Nutrition. David is known for calling out pseudoscience and misinformation, and promoting critical thinking and an evidence-based approach to health. For over 25 years, he's worked as a physician nutrition specialist, caring for critically ill patients who rely on life-saving nutrition support. He received the Excellence in Nutrition Education Award from the American Society for Nutrition. On this episode, he helps us debunk the vitamin supplement industry. Unwrap the truth about your food

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review:   1.     Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity  - NEJM   2.     Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3)– Lancet Diabetes Endocrinology    3.     Nutritional priorities to support GLP-1 therapy for Obesity – A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - American Journal of Clinical Nutrition 4.     Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events – Diab Care 5.     Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – NEJM For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Lee Thomas, chair of the American Society of Travel Advisors (ASTA) and one of the founders of NousTravel, talks with Alan Fine of Insider Travel Report about his long-term commitment to advancing the trade association and elevating the travel advisor profession. Thomas outlines his priorities, including advisor advocacy, education and professional standards, and reflects on ASTA's growth and renewed influence through events like the ASTA Caribbean Showcase. For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.  

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool.

Join Robert Scheer in this thought-provoking episode of Scheer Intelligence as he engages with sociologist Charlie Derber, author of Bonfire: American Sociocide - Broken Relations and the Quest for Democracy. This conversation delves into the complexities of modern American society, exploring the alarming trends of sociocide and the ramifications of systemic alienation amidst apparent prosperity.Derber, a prolific writer with 29 books to his name, presents a compelling argument about the forces at play in our current societal landscape, where individualism erodes community bonds and the quest for democracy feels increasingly distant. Robert and Charlie dissect the historical context of these issues, tracing the roots of contemporary authoritarianism and the role of elites in shaping the socio-political climate. Amidst the grim diagnosis, they also uncover rays of hope, examining the potential for grassroots movements and collective action to challenge the status quo. With insights that resonate deeply in today's political climate, this episode is not just an analysis of despair but also a call to recognize the cracks in the system where light can break through.Listen in as they discuss the contradictions inherent in a society at odds with itself and contemplate the future of democracy in a world grappling with profound social and economic upheaval. Tune in for a rich conversation that challenges conventional narratives and invites listeners to reflect on their role in shaping a more equitable society.

Dr. Amy Fallas is a PhD in History at UC Santa Barbara. She holds an MA in History from Yale and her research examines religious difference, charitable networks, and historical memory in the Middle East. Her work has been supported by the American Research Center in Egypt, the American Society for Church History, the Orthodox Christian Studies Center among others. She is the Associate Editor of the Arab Studies Journal and serves on the steering committees of the History of Christianity and Middle Eastern Christianity units of the American Academy of Religion. Her scholarship appears in History Compass and Islam and Christian–Muslim Relations and her essays are published in the Washington Post, Jadaliyya, Mada Masr, the Revealer, Sojourners and more. On this episode, we mostly discuss her article Brothers in the Resistance, research in Lebanon about connections between Latin America and the Middle East, titled Hermanos fi al-Muqawama, She is based in Beirut. Visit Sacred Writes: https://www.sacred-writes.org/carpenter-cohort-2025-jan Visit Amy Fallas: https://www.amyfallas.com/  

Pangaea Golf Architecture is a world-leading golf consultancy and course design firm, established in 2023. It's a Scottish–American strategic partnership between Jeffrey Danner (based in California) and Stuart Rennie (based in Glasgow), united by over 16 years of friendship and a shared philosophy: "One World – Better Together." On this episode of The Wednesday Match Play Podcast, brought to you by Eden Mill St Andrews, Jeffrey gives us an update on his life and introduces us to Pangea. He talks about where the name came from, how he and his business partner Stuart first met, their blog, his process for designing a golf hole, and his experience using AI in this space. He also shares his involvement with the American Society of Golf Course Architects and explains how they balance different time zones with him being based in California and Stuart in Glasgow. This was a technological conversation, and it was an honor having Jeffrey on the show. Let's tee off.

Zane Kerby, president and CEO of the American Society of Travel Advisors (ASTA), talks with Alan Fine of Insider Travel Report at the ASTA Caribbean conference in Jamaica about ASTA's legislative victories, commission payment tools and sverified travel advisor program. Kerby outlines current threats to the profession and urges advisors to join the fight through advocacy, education and unity, as well as such conferences as the ASTA Caribbean event. For more information, visit www.asta.org.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.  

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- American Society of Clinical Oncology (ASCO) 2025 Annual Meeting: Triple Negative Breast Cancer Updates - New Research on Triple Negative Breast Cancer Presented at ASCO - Triple Negative Breast Cancer-Specific Treatment Updates - Young Adults & Older Adult Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort, Quality of Life & Pain - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

Breaking down examples of why American society is broken. Ilhan Omar suddenly is worth as much as $30 million. How could that possibly happen? Johnny Heidt with guitar news. HEARD ON THE SHOW:Walz says he plans to call special session on gun laws in wake of Annunciation shootingMan who threatened to ‘shoot up' UnitedHealth campus found incompetent; State still intends to prosecutePowerball jackpot rises to an estimated $1.3 billion after no winning ticket soldSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Elevated GP: www.theelevatedgp.com Net32.com  Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram   Dr. Mandelaris attended the University of Michigan from undergraduate through dental school.  He completed a post-graduate residency program at the University of Louisville, School of Dentistry, where he obtained a certificate in the speciality of Periodontology as well as a Master of Science (M.S.) degree in Oral Biology.  Dr. Mandelaris is a Diplomate of the American Board of Periodontology and Dental Implant Surgery and has served as an examiner for Part II (oral examination) of the American Board of Periodontology's certification process. He is a Clinical Assistant Professor in the Department of Graduate Periodontics at the University of Illinois, College of Dentistry (Chicago, IL) and an Adjunct Clinical Assistant Professor at the University of Michigan, Department of Periodontics and Oral Medicine (Ann Arbor, MI).  Dr. Mandelaris is a Fellow in both the American and International College of Dentists. Dr. Mandelaris serves as an ad-hoc reviewer for the Journal of Periodontology and the International Journal of Oral and Maxillofacial Implants. In 2021, he was appointed as an Editorial Consultant to the International Journal of Periodontics and Restorative Dentistry. He has published over 40 scientific papers in peer-reviewed journals and has authored eight chapters in seven different textbooks used worldwide on subjects related to computer guided implantology, CT/CBCT diagnostics and surgically facilitated orthodontic therapy (SFOT). Dr Mandelaris is one of the recipients of the 2017 and the 2021 American Academy of Periodontology's (AAP) Clinical Research Award, an award given to the most outstanding scientific article with direct clinical relevance in Periodontics. A nationally recognized expert, he was appointed by AAP to co-chair the Best Evidence Consensus Workshop on the use of CBCT Imaging in Periodontics as well as co-author the academy's guidelines. In 2018, he was recognized with American Academy of Periodontology's Special Citation Award.  Dr. Mandelaris is the 2018 recipient of The Saul Schluger Memorial Award for Clinical Excellence in Diagnosis and Treatment Planning. Dr. Mandelaris currently serves on the American Academy of Periodontology Board of Trustees and has served as a Past President of the Illinois Society of Periodontists. He has served on several committees for the American Academy of Periodontology and is one of the AAPs recommended speakers on topics related to periodontics-orthodontics and imaging/implant surgery. He is a key-opinion leader for several industry leaders and holds memberships in many professional organizations, including the American Academy of Periodontology, Academy of Osseointegration, American Academy of Restorative Dentistry and the American Society of Bone and Mineral Research. Dr. Mandelaris is in private practice at Periodontal Medicine & Surgical Specialists, LLC. He limits his practice to Periodontology, Dental Implant Surgery, Bone Reconstruction and Tissue Engineering Surgery. He can be reached at 630.627.3930 or gmandelaris@periodontalmedicine.org.

A practitioner who grew up in China now living in the US overcame her struggle to express herself and became proficient and skilled at clarifying the truth in many different groups and circumstances. The process of learning to shed the CCP influence on her personality and become more thoughtful and considerate of others has been […]

How is AI changing resumes? Will a certification help you in a competitive job market? Find out from career activator Madelyn Mackie. Recorded at EA Ignite Spring 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Ever dreamed of running away to India, Egypt, or Greece without waiting on anyone else's schedule? Meet Alle Pierce of The Gallivant Society, as she and Michelle dish on building a luxury travel brand from the ground up. From accidentally launching a business with a Canva logo to curating transformative, friendship-fueled adventures for women across the globe, you'll get the inside scoop on what really goes into planning curated group trips. Sprinkle in tales of TV news burnout and launching a website that finally matches the five-star experience, this episode is proof that luxury doesn't have to be boring, and travel is always better with the right crew.   Alle Pierce is the Founder, Travel Designer, and Chief Galavant Officer at The Galavant Society: a company offering curated, small-group travel experiences for independent and curious women. Before launching TGS, Alle spent over a decade as a TV journalist and Emmy Award–winning host, telling stories on-air around the country. When she's not galavanting, she produces travel content for the Olympics and tourism boards, emcees events for the American Society of Travel Advisors, and proudly serves as the Godmother of a luxury river cruise ship. At its heart, The Galavant Society is more than just travel. It's a global community of women living boldly, on their own terms. ------------------------ In today's episode, we cover the following: Alle's career backstory Transition to the travel industry Organizing her first group trip Brand naming and evolution MKW collab: from merch to branding Brand strategy and visual identity development Signature items: the Galavant Scarf Scaling and structuring the business Website and sales experience upgrade The brand reveal "wedding" launch party Lasting impact and brand belonging Gifting and client loyalty Looking forward: plans for future trips and collaborations ---------------------- RESOURCES: Episode 229: Why Your Rebrand Deserves a Launch Party Episode 159: Travel Photography Secrets with Girl Gone Abroad Partner with MKW Creative Co. on your rebrand!   ----------------------- Guest info: To learn more about The Galavant Society and their luxurious tours, follow them on Instagram @TheGalavantSociety and visit their website, TheGalavantSociety.com. ----------------------- Boring packaging? Forgettable branding? Sticker Giant fixes that with custom stickers and labels designed to make your brand stick—literally. Use code KMA25 at stickergiant.com for 25% off your first order. ----------------------- WORK WITH MKW CREATIVE CO.   Connect on social with Michelle at: Kiss My Aesthetic Facebook Group Instagram Tik Tok ----------------------- Did you know that the fuel of the POD and the KMA Team runs on coffee? ;) If you love the content shared in the KMA podcast, you're welcome to invite us to a cup of coffee any time - Buy Me a Coffee! ----------------------- This episode is brought to you by Zencastr. Create high quality video and audio content. Get your first two weeks free at https://zencastr.com/?via=kma. ----------------------- This episode of the Kiss My Aesthetic Podcast is brought to you by Audible. Get your first month free at www.audible.com/kma.   This episode was edited by Berta Wired Theme music by: Eliza Rosevera and Nathan Menard

Dr. Sean Teebagy is a PGY-2 resident at the University of Massachusetts Chan Medical School. Dr. Teebagy earned his medical degree from U Mass Chan Medical School after studying psychology at the College of The Holy Cross in Worcester, (woorster) Massachusetts. Dr. Teebagy's team recently won the Inaugural Eye Trauma 2025 Hackathon hosted by the American Society of Ophthalmic Trauma, as well as an award for best poster for his research in ocular trauma in Major League Baseball.

Sherif Nasser is an experienced quality professional with over 24 years in the construction industry. He has worked in senior roles such as Business Risk Director and Quality Consultant for international companies. Since 2015, he has been a global public speaker and has trained thousands of professionals in quality management. He is a Fellow of the Chartered Quality Institute, a Certified EFQM Assessor, and a recognised expert by American Society of Quality. He also holds ASQ certifications as Certified Manager of Quality - Organisational Excellence and Certified Construction Quality ManagerSherif founded free study channels that have helped hundreds of students around the world and has mentored more than 50 professionals from different countries. He is known for introducing the title “Organization Doctor” to promote the modern role of quality leaders.

In this episode of the Investor Fuel podcast, host Skyler Byrd interviews Susan Vanderburgh, a remarkable individual who shares her inspiring journey from being born in Vietnam to becoming a successful real estate investor and nonprofit founder. Susan discusses her early life experiences, including her family's escape from Vietnam, her transition into the real estate industry, and her mission to provide housing for veterans, domestic abuse survivors, and youth aging out of foster care through her nonprofit, the American Society of Community Benefits. The conversation also touches on the challenges of acquiring properties for transitional housing and the growing trend in this niche market.   Professional Real Estate Investors - How we can help you: Investor Fuel Mastermind:  Learn more about the Investor Fuel Mastermind, including 100% deal financing, massive discounts from vendors and sponsors you're already using, our world class community of over 150 members, and SO much more here: http://www.investorfuel.com/apply   Investor Machine Marketing Partnership:  Are you looking for consistent, high quality lead generation? Investor Machine is America's #1 lead generation service professional investors. Investor Machine provides true ‘white glove' support to help you build the perfect marketing plan, then we'll execute it for you…talking and working together on an ongoing basis to help you hit YOUR goals! Learn more here: http://www.investormachine.com   Coaching with Mike Hambright:  Interested in 1 on 1 coaching with Mike Hambright? Mike coaches entrepreneurs looking to level up, build coaching or service based businesses (Mike runs multiple 7 and 8 figure a year businesses), building a coaching program and more. Learn more here: https://investorfuel.com/coachingwithmike   Attend a Vacation/Mastermind Retreat with Mike Hambright: Interested in joining a “mini-mastermind” with Mike and his private clients on an upcoming “Retreat”, either at locations like Cabo San Lucas, Napa, Park City ski trip, Yellowstone, or even at Mike's East Texas “Big H Ranch”? Learn more here: http://www.investorfuel.com/retreat   Property Insurance: Join the largest and most investor friendly property insurance provider in 2 minutes. Free to join, and insure all your flips and rentals within minutes! There is NO easier insurance provider on the planet (turn insurance on or off in 1 minute without talking to anyone!), and there's no 15-30% agent mark up through this platform!  Register here: https://myinvestorinsurance.com/   New Real Estate Investors - How we can work together: Investor Fuel Club (Coaching and Deal Partner Community): Looking to kickstart your real estate investing career? Join our one of a kind Coaching Community, Investor Fuel Club, where you'll get trained by some of the best real estate investors in America, and partner with them on deals! You don't need $ for deals…we'll partner with you and hold your hand along the way! Learn More here: http://www.investorfuel.com/club   —--------------------

Your liver could be silently struggling right now and the good news is, you can turn it around. In this episode, I dive deep into the topic of metabolic dysfunction-associated steatotic liver disease, also known as fatty liver disease. I explain what it is, why the medical community updated the name, and why it matters for long-term health. I highlight who is most at risk, including people with obesity, diabetes, high blood pressure, or high cholesterol and why the condition is often called a “silent disease” since many don't realize they have it. I also break down the potential dangers if it progresses, from inflammation to cirrhosis, and share the encouraging news that it's often reversible with lifestyle changes. My goal is to empower listeners to protect their liver and overall health with small, sustainable changes.  Take control of your health and tune in to this episode to learn how you can prevent, reverse, and protect your liver from fatty liver disease with simple, sustainable steps!   Episode Highlights: What MASLD is and why the name changed from NAFLD Why fatty liver disease is becoming more common and who's most at risk Signs, symptoms, and why it's often called a “silent disease” Potential complications, including inflammation, fibrosis, and cirrhosis How fatty liver is diagnosed through blood tests, imaging, or scans Lifestyle strategies to reverse or prevent progression  The role of managing diabetes, cholesterol, and blood pressure in protecting liver health FDA-approved medications such as Wegovy and others that may help in treatment Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Send us a textWhat if the way we quantify pathology is more guesswork than science? In this episode of DigiPath Digest, I take you through the latest research where AI is not just supporting but challenging traditional methods of image analysis in neuropathology, nephrology, hematology, and cytology. From Boston brain banks to Mayo Clinic kidney models, we look at how advanced AI compares to human vision—and where it already outperforms us.Episode Highlights:[00:02:49] Neuropathology image analysis (Boston VA & BU) – Why traditional semiquantitative scoring often fails, and how AI-based density quantification reveals more subtle pathology in CTE.[00:13:16] Chronic kidney changes with AI (Mayo Clinic, Cambridge, Emory, Geneva) – A 20-class AI model trained on 20,500 annotations, showing how multiclass segmentation outperforms human guesswork in renal pathology.[00:21:09] Digital hematology review (University of Pennsylvania) – Current hurdles in AI for blood and bone marrow evaluation: regulatory oversight, data standardization, and resistance to change.[00:25:52] AI in cytology review (Journal of Cytopathology) – From BD FocalPoint to deep learning: two decades of digital cytology, stagnation, and why adoption still lags despite proven benefits.[00:32:09] Neuropathology goes digital – Where digital neuropathology is already routine (Ohio State, Mayo Clinic, Leeds, Granada) and why this specialty is crucial for pushing adoption.[00:34:19] Personal note – Why I believe learning, sharing, and experimenting with AI tools now will shape the way we practice pathology tomorrow.Resources from this EpisodeComparison of quantitative strategies in neuropathologic image analysis – Boston VA / BU Brain Bank study.Multiclass AI model for chronic kidney changes – Mayo Clinic, Cambridge, Emory, Georgia Tech, Geneva collaboration.Review: Digital hematology in the AI era – International Journal of Laboratory Hematology.Review: AI and machine learning in cytology – Journal of the American Society of Cytopathology.Digital Pathology 101 (by me, Dr. Aleksandra Zuraw) – Free PDF & Amazon print edition.Pathology AI Makeover Course – Practical training for AI in pathology workflows.Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Terry Whalin worked as a magazine editor and his magazine work has appeared in more than 50 publications. A former book acquisitions editor for several publishers and a former literary agent, Terry is an acquisitions editor at Morgan James Publishing. #podcasting #podmatch #TerryWhalin====================Join Podmatch ⁠⁠ https://www.joinpodmatch.com/roy⁠Speaking Podcast Social Media / Coaching My Other Podcasts ⁠ https://bio.link/podcaster ⁠====================Bio of Terry WhalinW. Terry Whalin understands both sides of the editorial desk--as an editor and a writer. He worked as a magazine editor and his magazine work has appeared in more than 50 publications. A former book acquisitions editor for several publishers and a former literary agent, Terry is an acquisitions editor at Morgan James Publishing. He has written more than 60 books through traditional publishers in a wide range of topics from children's books to biographies to co-authored books. Over 20 years ago, in eleven days, Terry wrote a diet book called First Place by Carole Lewis which has sold over 100,000 copies. Terry's newest book is 10 Publishing Myths, Insights Every Author Needs to Succeed (Morgan James Publishing). Tonight, everyone can get a physical copy of 10 Publishing Myths for only $10 including the shipping plus it comes with over $200 of free bonuses. You can get this special offer at publishingoffer.com He is a popular speaker and teacher at numerous writers' conferences and an active member of the American Society of Journalists and Authors. Terry and his wife, Christine, live in Southern California.What we Discussed: 00:15 Who is Terry Whalin01:18 What is an Acquisitions Editor02:15 Can Podcasters Use Content to Create a Book03:40 There are More places to Publish your Book along with Amazon04:30 What Books are Selling06:00 How do Authors Protect themselves with Publishers07:29 When are Royalities Paid08:03 Join the Authors Guild10:25 Ensure you have the Proper Disclaimer11:00 Getting on Podcasts and his Experience14:18 Using Ai for Podcasts16:45 His Experience with different recording platforms19:40 Not all Guests want shorts or promote the Episode22:50 Do you encourage the Authors to go on Books25:30 How to get his Book for $10 including Shipping26:55 Getting the Authors to go on a Podcast Tour29:10 Best way to Launch a Book31:55 Why a 1 Star Review can be beneficial34:50 Chicken Soup for the Soul Pitches36:40 His successful Blog38:30 Myth 1 That you will Make a lot of Money with a Book39:55 Do not Compare Youself with Famous Creators41:15 Pick a few Platforms and be engaging43:10 Authors Rejected 160 times44:40 1001 Ways to Market Your Book46:05 Podcasters Ask me what is the 1 thing that will improve their Ratings49:50 Having Audio Books55:25 How Does the Author Win Selling a Book with Shipping for $10  How to Contact Terry Whalinhttps://terrywhalin.com/Get the Book as Discussed https://www.marketing4books.com/us-ordhttps://dl.bookfunnel.com/aq5j0acu9ohttps://x.com/terrywhalinhttps://www.linkedin.com/in/terrywhalin/___________________

On Upgrade America, we share our own thoughts and opinions. When we talk about Israel or any global issue, it's for discussion and perspective — not to spread hate or target any group. We encourage listeners to think critically and check out different sources for themselves.SummaryIn this episode of Upgrade America, hosts Cameron Broad and his co-host delve into pressing issues surrounding American involvement in Israel, recent events in Gaza, and the implications of military actions. They discuss the economic disparities faced by average Americans, the controversy over Florida's pro-Israel license plate, and the influence of powerful families like the Rothschilds in shaping geopolitical landscapes. The conversation also touches on the challenges of free speech within the military and the potential consequences of inaction in the face of growing authoritarianism. The episode concludes with a call to action for listeners to remain informed and engaged in the political process.Chapters00:00 Introduction to the Podcast and Themes01:23 Critique of Israel and American Involvement04:36 Recent Events in Gaza and Media Coverage07:20 American Military and First Amendment Rights10:20 Economic Disparities and Corporate Influence12:36 Florida's Pro-Israel License Plate Controversy15:28 Geopolitical Connections and Jewish Influence19:34 Discussion on the Talmud and Controversial Topics22:32 Military Investigations and Free Speech25:21 The State of American Society and Potential Outcomes30:16 Concluding Thoughts and Future Implications

“She's triple negative and has a very, very aggressive tumor. Instead of going on spring break that year, she sat in our chemo room and got chemo. Her friends from college are good to try to keep her involved and try to surround her and encourage her, but they're right now in very, very different spots in their lives. She's fighting for her life; her friends are fighting for the grade they get in a class—and that's different,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about metastatic breast cancer in adolescent and young adult patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities Episode 307: AYAs With Cancer: Financial Toxicity Episode 300: AYAs With Cancer: End-of-Life Care Planning ONS Voice articles: ‘Cancer Ghosting' May Add Another Layer of Emotional Burden for Patients Discoveries in Race-Related Breast Cancer Biomarkers May Improve Precision Treatments What Is HER-2-Low Breast Cancer? What Oncology Nurses Need to Know About Supporting AYAs With Cancer ONS books: Guide to Breast Cancer for Oncology Nurses Oncology Nursing Forum articles: An Integrative Review of the Role of Nurses in Fertility Preservation for Adolescents and Young Adults With Cancer Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS huddle cards: Altered Body Image Fertility Preservation Sexuality Other ONS resources: Breast Cancer Learning Library Fertility Preservation in Individuals With Cancer ONS Biomarker Database American Cancer Society's breast cancer resources American Society of Clinical Oncology continuing education resources Elephants and Tea Life, Interrupted Livestrong National Cancer Institute's breast cancer resources Stupid Cancer Young Survival Coalition To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we use ‘adolescent and young adult,' we're really talking about age 19–35. Some groups will say 15–39, but right around that age. When we think about that age, think about what all could be going on during those ages. Late teenagers, they may be going off to college, they may be graduating high school, trying to set up their own life, trying to become independent from mom and dad. If you're talking about early to mid 30s, you could be talking about young parents, young career folks. So, just setting that into place makes you realize this can be a very tumultuous time for folks.” TS 2:06 “Unfortunately, this group tends to have more aggressive subtypes. We see more triple-negative in this group. We see more hormone-negative, HER2-positive in this group. Normal breast cancer cells should be stimulated by hormone. They are stimulated by hormones. So when you have a breast cancer cell that is not driven by hormones, it's much more difficult to treat. We tend to see more aggressiveness in these tumors. We also see a higher incidence in non-Caucasian folks in this age group compared to the older age groups.” TS 4:53 “I think we have gotten much better about understanding the importance of fertility preservation and getting reproductive endocrinologists in, sooner rather than later. If we have earlier-stage cancers and we have patients that want to try to preserve eggs, preserve fertility, sperm banking. … If you have that time to talk to them—maybe a 21-year-old—the primary thing on her mind is not how many children she wants to have one day. Maybe she's not even thought about having kids yet. It's still a question you need to [ask]. Do you want to try to preserve fertility? Do you want to try to harvest some eggs? That's a conversation that needs to be had and is very, very important for that age group.” TS 10:35 “One thing that helps is if you can get them [into] reputable support groups with people their own age that are going through what they're going through. Someone else that doesn't have hair, someone else that isn't going to make it to the big board meeting or isn't going to get the promotion this year because they've had to take a medical leave. Someone else that understands it differently.” TS 16:47 “In breast cancer, many of those biomarkers just get reflexed. And what I mean by reflexed is a breast cancer pathology comes through, or a breast cancer specimen comes through, and it just automatically gets tested for X, Y, Z. HER2 and of course ER/PR. Now we understand that we don't just need to know whether they're HER2 positive or HER2 negative. We need to know: What is the IHC score? And even if the IHC score is zero, is there any membrane staining? And then we need to know what's their ESR1, their PTEN, their AKT, their PIK3CA. Those are so important to know.” TS 18:11 “I think it's important to try to remember what our priorities were when we were in our 20s—what our priorities were when we were starting out as young mothers or starting out our career. Because that's where these folks are. … I can't imagine in the midst of college, when I'm trying to be independent, to suddenly have to be at home and rely on my mom to take me to my chemo appointment. … So I think one really important bias is to remember where they are in the developmental stages of life. They're not 40-something. They haven't lived X amount of life, and we need to take a step back and try to remember when we were their age, what was important to us? Where were our priorities at that point? And then hear them when they're telling us what's important to them.” TS 29:22 “From a female standpoint … we frequently throw these patients into menopause or have early menopausal symptoms, and I think we forget how devastating that can be. … They now are at higher risk for osteopenia or osteoporosis. … And then we tell people, ‘Be as normal as possible, get back and do those normal things.' Well, they're in a relationship, and they want to be intimate [but] suddenly having sexual intercourse is incredibly painful. Or if it's not painful, sometimes they've just lost pure interest in that. They don't feel confident about their body. All of those things need to be addressed because patients are trying to live each day as normally as possible.” TS 31:55 

ResourcesClick here to learn about United Ostomy Associates of America (UOAA) National Quality Ostomy Care Campaign, including the Ostomy and Continent Diversion Patient Bill of Rights,.Click here to view a list of patient resources that the WOCN Society has curated, including services, products, and publications. You can also bookmark and/or share the following web address with your colleagues and patients: IDeserveaWOCNurse.com.Click here to view and use the Peristomal Skin Assessment Guide for Clinicians and Consumers,. You can also bookmark and/or share the following web address with your colleagues and patients: psag.wocn.org.Click here to learn more about Janet's session at WOCNext® 2025, “I Have an Ostomy, Where can I go?: Challenges of Setting Up An Ostomy Clinic,.”The WOCN Society, in collaboration with the American Society of Colon and Rectal Surgeons (ASCRS) and the American Urological Association (AUA), developed the educational resources to assist clinicians in selecting an effective stoma site. Click here to review these resources.If you're a healthcare professional looking to deepen your knowledge of ostomy care, explore the joint WOCN and ASCRS Ostomy Care Management (OCM) Program—an evidence-based, online education designed to enhance care delivery and improve outcomes for individuals living with an ostomy. Click here to learn more.Journal of Wound, Ostomy, and Continence Nursing (JWOCN®) articles referenced in this episode:Bridging the Gap: Perceived Educational Needs in the Inpatient to Home Care Setting for the Person With a New OstomyLessons Learned About Peristomal Skin Complications Secondary Analysis of the ADVOCATE TrialOstomy and Continent Diversion Patient Bill of Rights Research Validation of Standards of CareOther articles referenced in this episode: The ostomy leak impact tool: development and validation of a new patient-reported tool to measure the burden of leakage in ostomy device usersImpact of stoma leakage in everyday life: data from the Ostomy Life Study 2019Factors impairing quality of life for people with an ostomy About the SpeakerJanet has enjoyed 40 years in WOC Nursing. Although her early nursing career focus was critical care as a certified critical care registered nurse she certified as a CWOCN in 1985. In 1996, she embarked in a private WOC practice, first as a partnership and then as sole proprietor practicing across the continuum with a focus on ostomy care coupled with a passion for patients attaining their desirable quality of life. Janet worked in outpatient ostomy clinics serving different populations and challenges... adding a bit of spice to her practice and recently retired from patient care.Janet lectures nationally and internationally, has published on Quality of Life of People Living with an Ostomy and co-authored both a home study course on Wound Management & Healing and an educational video on Common Perineal Skin Injuries, and. She participates in Ostomy and Incontinence Associated Dermatitis research and actively participates with WOCN and industry to move ostomy care forward. Her peers awarded her the PCR* ET Nurse of the Year Award in 1996, PCR* President's Award in 2000 and PCR* Professional Educational Award in 2004.*PCR stands for the Pacific Coast Region of the WOCN Society, what is now known as the Pacific Coast Chapter of the WOCN Society (or PCC for short). The WOCN Society has 11 chapters throughout the country that support WOCN members at a local level with resources, education, networking opportunities, social gatherings, timely information, and more. For additional information, please visit wocn.org/Chapters. Editing and post-production work for this episode was provided by The Podcast Consultant.

Host Dr. Shawn McNeil is joined by Dr. Robert Sherrick to discuss his new article Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs featured in the July/August issue of the Journal of Addiction Medicine.   Robert Sherrick, MD, DFASAM, is chief science officer for Community Medical Services, a company that serves patients through over 70 Opioid Treatment Programs in 12 states. He also has experience working at an inpatient addiction treatment facility, Pathways Treatment Center, treating all forms of substance use disorders and dual diagnosis patients.   Dr. Sherrick has been providing medication treatment for opioid use disorder since 2003, initially in an office setting using buprenorphine and subsequently with methadone in Opioid Treatment Programs. He established a state-wide buprenorphine treatment program for VA Montana with extensive use of telemedicine. He is board certified in internal medicine and addiction medicine through the American Board of Preventive Medicine. He is past president of the Northwest Chapter of the American Society of Addiction Medicine (ASAM). - Article: Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Access to quality healthcare is still out of reach for millions worldwide — particularly in low- and middle-income countries and underserved rural areas. One of the biggest drivers of this gap is a shortage of trained healthcare workers, a challenge made worse by workforce migration, limited local training opportunities, and uneven distribution of resources.In this episode of Healthcare Perspectives, host Hagen Weissapfel, Director of Education and Customer Services for Global Access to Care at Siemens Healthineers, is joined by Melissa Culp, Executive Vice President of Member Engagement at the American Society of Radiologic Technologists (ASRT), and Dr. Geoff Ibbotson, surgeon and Executive Director of the Global Surgery Foundation (GSF). Together, they explore how education and training — scaled through digital innovation and local partnerships — can transform access to care for underserved communities.From stories of practicing in isolation in remote Nepal, to advancing imaging education in Malawi, to building global learning platforms like SURGHub, Melissa and Geoff share how sustainable, in-country solutions can empower healthcare professionals, break down systemic barriers, and save lives.What you'll learn in this episode:Why education is one of the most sustainable forms of impact in global healthHow digital learning platforms like SURGHub are connecting providers in over 200 countriesThe role of local leadership and trust in building effective training programsHow public awareness campaigns can inspire the next generation of medical imaging professionalsThe life-or-death consequences of gaps in surgical technology access — and how training can close themWhy small, targeted investments can yield measurable improvements in health outcomesConnect with Hagen WeissapfelLinkedInConnect with Melissa CulpLinkedInConnect with Geoff IbbotsonLinkedIn Hosted on Acast. See acast.com/privacy for more information.

Join Elevated GP: www.theelevatedgp.com Net32.com  Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram   Dr. Mandelaris attended the University of Michigan from undergraduate through dental school.  He completed a post-graduate residency program at the University of Louisville, School of Dentistry, where he obtained a certificate in the speciality of Periodontology as well as a Master of Science (M.S.) degree in Oral Biology.  Dr. Mandelaris is a Diplomate of the American Board of Periodontology and Dental Implant Surgery and has served as an examiner for Part II (oral examination) of the American Board of Periodontology's certification process. He is a Clinical Assistant Professor in the Department of Graduate Periodontics at the University of Illinois, College of Dentistry (Chicago, IL) and an Adjunct Clinical Assistant Professor at the University of Michigan, Department of Periodontics and Oral Medicine (Ann Arbor, MI).  Dr. Mandelaris is a Fellow in both the American and International College of Dentists. Dr. Mandelaris serves as an ad-hoc reviewer for the Journal of Periodontology and the International Journal of Oral and Maxillofacial Implants. In 2021, he was appointed as an Editorial Consultant to the International Journal of Periodontics and Restorative Dentistry. He has published over 40 scientific papers in peer-reviewed journals and has authored eight chapters in seven different textbooks used worldwide on subjects related to computer guided implantology, CT/CBCT diagnostics and surgically facilitated orthodontic therapy (SFOT). Dr Mandelaris is one of the recipients of the 2017 and the 2021 American Academy of Periodontology's (AAP) Clinical Research Award, an award given to the most outstanding scientific article with direct clinical relevance in Periodontics. A nationally recognized expert, he was appointed by AAP to co-chair the Best Evidence Consensus Workshop on the use of CBCT Imaging in Periodontics as well as co-author the academy's guidelines. In 2018, he was recognized with American Academy of Periodontology's Special Citation Award.  Dr. Mandelaris is the 2018 recipient of The Saul Schluger Memorial Award for Clinical Excellence in Diagnosis and Treatment Planning. Dr. Mandelaris currently serves on the American Academy of Periodontology Board of Trustees and has served as a Past President of the Illinois Society of Periodontists. He has served on several committees for the American Academy of Periodontology and is one of the AAPs recommended speakers on topics related to periodontics-orthodontics and imaging/implant surgery. He is a key-opinion leader for several industry leaders and holds memberships in many professional organizations, including the American Academy of Periodontology, Academy of Osseointegration, American Academy of Restorative Dentistry and the American Society of Bone and Mineral Research. Dr. Mandelaris is in private practice at Periodontal Medicine & Surgical Specialists, LLC. He limits his practice to Periodontology, Dental Implant Surgery, Bone Reconstruction and Tissue Engineering Surgery. He can be reached at 630.627.3930 or gmandelaris@periodontalmedicine.org.

This week's episode is all about the silver lining. Yes, there are tragedies in this episode - but look for the good that came out of these devastating events. Hannah covers Henry Bergh, who founded the American Society for the Prevention of Cruelty to Animals (ASPCA), and how he helped Mary Ellen Wilson, a child abuse survivor whose case changed laws across the country. Sheena covers the devastating Natchez Rhythm Club fire and the resulting change in safety standards. Lori cheers us up by sharing the story of Rose O'Neill, who created Kewpie dolls.

Did you know that nearly one in three people with obesity may have fatty liver disease without even knowing it? In this episode, I talk about groundbreaking news in obesity and liver health, focusing on the FDA's recent approval of WeGovy to treat metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced fibrosis. I share a personal story about a friend who once struggled with fatigue, abnormal liver tests, and fatty liver disease, highlighting how limited treatment options used to be. I explain what MASH is, why it's so serious, and how common it is, especially among people with obesity and metabolic syndrome.  Furthermore, I dive into the ESSENCE trial, which showed that WeGovy not only improved liver inflammation and scarring but in some cases even reversed the disease, all while emphasizing that it works best when combined with lifestyle changes like healthy eating and regular activity.  Don't miss this episode where I break down the latest breakthrough in liver and weight loss care that could change your health journey!   Episode Highlights: FDA approval of WeGovy for treating MASH with fibrosis The ESSENCE trial results showing improvements in liver health Understanding what MASH is and why it's so common Importance of combining medication with lifestyle changes Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Join Alicia Stillman of the American Society for Meningitis Prevention, as she shares a very personal story of loss that might change how you view meningitis vaccination.Presenter:Alicia Stillman, MBA, MPHPatient AdvocateCo-Executive Director, American Society for Meningitis PreventionExecutive Director, Emily Stillman FoundationDetroit, MichiganLink to full program:https://bit.ly/4mYvTXQRegister for the practical symposium:https://bit.ly/4mUOsvVGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Michael Lynch, Ph.D., Director of the Center for Mechanisms of Evolution at Arizona State University and Vaughn Cooper, Ph.D., professor of Microbiology and Molecular Genetics at the University of Pittsburgh, School of Medicine, examine the origins and trajectory of early microbial life (EML) and discuss the collaborative report between the American Academy of Microbiology and the Gordon and Betty Moore Foundation, which explores the journey of life on Earth, from non-living chemical compounds to early unicellular life, to the vast diversity of organisms we see today. This episode is brought to you by the American Academy of Microbiology, a think tank at American Society for Microbiology and the Gordon and Betty Moore Foundation, which has been dedicated to advancing scientific discovery for the past 25 years. Links for This Episode: Project Report Early Microbial Life: Our Past, Present and Future. Article: The Great Oxidation Event: How Cyanobacteria Changed Life. MTM Podcast: From Hydrothermal Vents to Cold Seeps: How Bacteria Sustain Ocean Life With Nicole Dubilier. Take the MTM listener survey! 

Episode 060 | Iris Rubin, MD is the founder of SEEN, a patented, award-winning, science-backed, mission-driven haircare system. At SEEN, it's all about great haircare that won't do damage to your skin.Dr. Rubin received her undergraduate degree with honors from Stanford University, and her medical degree from Harvard Medical School. She did her dermatology residency at the University of Chicago and Harvard Medical School, and served as academic chief resident at Harvard. She completed a laser surgery fellowship at Massachusetts General Hospital and Wellman Center for Photomedicine.Prior to launching SEEN, Dr. Rubin's previous positions include Medical Director of the Dermatologic and Vascular Laser Surgery Program at Children's National Medical Center in Washington D.C., Dermatologist at Massachusetts General Hospital, and a faculty member at Harvard Medical School.Dr. Rubin has been an invited speaker at meetings sponsored by the American Society for Laser Medicine and Surgery (ASLMS), American Academy of Dermatology (AAD), American Society for Dermatologic Surgery (ASDS), Washington D.C. Dermatological Society, and Children's National Medical Center.This episode was recorded on February 3rd, 2025.Connect with and learn from Dr. Rubin and SEENSEENThe Science Behind SEENFind Your SEEN RegimenMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.Above & Beyond DermatologyNutrafol -- special pricing and physician exclusive productsNeoGenesis -- my favorite source of stem cell released molecules for skin/hairSilagen.biz -- physician dispensed scar refinement products delivered to your door (use practice code 1206240832P)NewsletterLinkedInFacebookDr. Lewellis on InstagramAbove & Beyond Dermatology on InstagramYouTubeTikTokTwitter/XChange Your Mind, Change Your LifeSoMeDocs (Doctors on Social Media)Pippa!

CardioNerds (Drs. Rick Ferraro and Georgia Vasilakis Tsatiris) discuss ATTR cardiac amyloidosis with expert Dr. Justin Grodin. This episode is a must-listen for all who want to know how to diagnose and treat ATTR with current available therapies, as well as management of concomitant diseases through a multidisciplinary approach. We take a deep dive into the importance of genetic testing, not only for patients and families, but also for gene-specific therapies on the horizon. Dr. Grodin draws us a roadmap, guiding us through new experimental therapies that may reverse the amyloidosis disease process once and for all.  Audio editing by CardioNerds academy intern, Christiana Dangas. This episode was developed in collaboration with the American Society of Preventive Cardiology and supported by an educational grant from BridgeBio.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: You must THINK about your patient having amyloid to recognize the pattern and make the diagnosis. Start with a routine ECG and TTE, and look for a disproportionately large heart muscle with relatively low voltages on the ECG.  Before you diagnose ATTR amyloidosis, AL amyloidosis must be ruled out (or ruled in) with serum light chains, serum/urine immunofixation, and/or tissue biopsy.  Genetic testing is standard of care for all patients and families with ATTR amyloidosis, and the future is promising for gene-specific treatments. Current FDA-approved treatments for TTR amyloidosis are TTR stabilizers and TTR silencers, but TTR fibril-depleting agents are on their way.  Early diagnosis of ATTR affords patients maximal benefit from current amyloidosis therapies.   TTR amyloidosis patients require a multidisciplinary approach for success, given the high number of concomitant diseases with cardiomyopathy.  Notes: Notes: Notes drafted by Dr. Georgia Vasilakis Tsatiris.  What makes you most suspicious of a diagnosis of cardiac amyloidosis from the typical heart failure patient?  You must have a strong index of suspicion, meaning you THINK that the patient could have cardiac amyloidosis, to consider it diagnostically. Some characteristics or “red flags” to not miss:   Disproportionately thick heart muscle with a relatively low voltages on EKG   Bilateral carpal tunnel syndrome – estimated that 1 in 10 people >65 years old will have amyloidosis   Previously tolerated antihypertensive medications  Atraumatic biceps tendon rupture   Bilateral carpal tunnel syndrome  Spinal stenosis   Concomitant with other diseases: HFpEF, low-flow low-gradient aortic stenosis  How would you work up a patient for cardiac amyloidosis?   Start with a routine ECG (looking for disproportionally low voltage) and routine TTE (looking for thick heart muscle)  CBC, serum chemistries, hepatic function panel, NT proBNP, and troponin levels  NOTE: It is critical to differentiate between amyloid light chain (AL amyloidosis) and transthyretin ATTR amyloidosis, as both make up 95-99% of amyloidosis cases.   Obtain serum free light chains, serum & urine electrophoresis, and serum & urine immunofixation to rule out AL amyloidosis. (See table below)  AL Amyloidosis ATTR Amyloidosis  → Positive serum free light chains and immunofixation (Abnormal M protein) → Tissue biopsy (endomyocardial, fat pad) to confirm diagnosis → Negative serum free light chains and immunofixation (ruled out AL amyloidosis) → Cardiac scintigraphy (Technetium pyrophosphate with SPECT imaging)  What treatment options do we have to offer now for ATTR CM, and how has this compared to prior years?   Before 2019, treatment options were limited outside of cardiac tr...

Interview with Author Terry Whalin about his book, "10 Publishing Myths."===============================================

The world is becoming pixelated. As computers and other digital devices become ubiquitous, human knowledge and communication and information is gradually being converted into, and manipulated as, strings of bits. What does that really mean, and what are the ramifications going forward? Alvy Ray Smith is a computer scientist, co-founder of Pixar, and author of A Biography of the Pixel. We go through the journey of how he helped make computer animation a reality, and the implications of what he calls the "Great Digital Convergence."Blog post with transcript: https://www.preposterousuniverse.com/podcast/2025/08/18/325-alvy-ray-smith-on-pixar-pixels-and-the-great-digital-convergence/Support Mindscape on Patreon.Alvy Ray Smith received a Ph.D. in computer science from Stanford University. He has been a professor of electrical engineering and computer science at New York University, a member of the Computer Graphics Lab at the NY Institute of Technology, director of computer graphics at Lucasfilm, and cofounder of Pixar and Altamira. He is a member of the National Academy of Engineering and a Fellow of the America Association for the Advancement of Science as well as the American Society of Genealogists. He is the winner of two technical Academy Awards.Web siteGoogle Scholar publicationsWikipediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lawfare Legal Fellow Mykhailo Soldatenko sits down with Oona Hathaway, Yale Law Professor and President-elect of the American Society of International Law, to discuss how the current world events are harming the norm prohibiting the use of force in international relations, why that's troubling, and what to do about it. They chat about the current U.S. administration's policies, recent strikes on Iran, and the implications for the norm from a potential negotiated settlement in the Russia-Ukraine war. You may want to look at the following pieces relevant to the discussion: “Might Unmakes Right: The Catastrophic Collapse of Norms Against the Use of Force,” by Oona A. Hathaway and Scott J. Shapiro“There's Still No Reason to Think the Kellogg-Briand Pact Accomplished Anything,” by Stephen M. Walt“Trump's Strikes on Iran Were Unlawful. Here's Why That Matters,” by Oona A. HathawayTo receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.